Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HR-positive, HER2-negative Breast Neoplasms”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 18 of 0 results

Not applicableStudy completedNCT06086340
What this trial is testing

Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.

Who this might be right for
Breast Cancer
Pfizer 779
Testing effectiveness (Phase 2)Study completedNCT06465368
What this trial is testing

Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause

Who this might be right for
Breast Cancer
Pfizer 121
Not applicableStudy completedNCT06311383
What this trial is testing

A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line Treatment

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 2,610
Testing effectiveness (Phase 2)UnknownNCT05411380
What this trial is testing

Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.

Who this might be right for
Breast Cancer
wang shusen 73
Large-scale testing (Phase 3)Ended earlyNCT01633060
What this trial is testing

A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi

Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals 432
Large-scale testing (Phase 3)Active Not RecruitingNCT02513394
What this trial is testing

PALbociclib CoLlaborative Adjuvant Study

Who this might be right for
Breast Cancer
Alliance Foundation Trials, LLC. 5,796
Not applicableStudy completedNCT05478590
What this trial is testing

Describe Treatment Patterns of Advanced Breast Cancer in Poland in the Real-world Data Setting

Who this might be right for
Breast Neoplasms
Pfizer 440
Early research (Phase 1)Active Not RecruitingNCT05266105
What this trial is testing

Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients

Who this might be right for
Breast Cancer
Olema Pharmaceuticals, Inc. 60
Testing effectiveness (Phase 2)Looking for participantsNCT05983107
What this trial is testing

Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer

Who this might be right for
HR+/HER2- Advanced Breast CancerTargeted Therapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 102
Large-scale testing (Phase 3)Looking for participantsNCT05851014
What this trial is testing

GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Who this might be right for
Breast Cancer
Genor Biopharma Co., Ltd. 350
Testing effectiveness (Phase 2)Looking for participantsNCT07368998
What this trial is testing

To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 80
Early research (Phase 1)Looking for participantsNCT06139107
What this trial is testing

RADIANT: Pre-op Radiation With Abemaciclib and Letrozole

Who this might be right for
Breast Cancer
Mridula George, MD 15
Post-approval studies (Phase 4)Study completedNCT02248571
What this trial is testing

Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab

Who this might be right for
Breast Cancer RecurrentHER2/Neu-negative Carcinoma of BreastHormone Receptor Positive Malignant Neoplasm of Breast
iOMEDICO AG 85
Post-approval studies (Phase 4)Not Yet RecruitingNCT07162259
What this trial is testing

Cohort Study on Sequential ADC Therapy in HR-positive/HER2-negative Advanced Breast Cancer

Who this might be right for
Breast Neoplasms
Yan Xue 40
Testing effectiveness (Phase 2)Looking for participantsNCT05608252
What this trial is testing

VS-6766+Abema+Fulv in Met HR+/HER- BC

Who this might be right for
Breast CancerHormone Receptor-positive Breast CancerHormone Receptor Positive HER-2 Negative Breast Cancer
Adrienne G. Waks 63
Post-approval studies (Phase 4)Active Not RecruitingNCT05161195
What this trial is testing

Roll-over Study to Allow Continued Access to Ribociclib

Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals 134
Early research (Phase 1)Looking for participantsNCT06625775
What this trial is testing

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Who this might be right for
Solid Tumor, AdultMetastatic Breast CancerAdvanced Breast Cancer+8 more
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) 392
Early research (Phase 1)Looking for participantsNCT07358377
What this trial is testing

A Trial of HRS-6209-205 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Combination Therapy in Subjects With HR-Positive/HER2-Negative Cancer

Who this might be right for
Breast Cancer
Atridia Pty Ltd. 15